Aveo Pharma initiated with a Sell, $0 price target at National Securities. National Securities initiated Aveo Pharmaceuticals with a Sell and $0 price target saying recent share appreciation is “totally unwarranted.” The firm’s analyst expects interim and final Phase 3 overall survival data updates to fail to support a Tivozanib NDA filing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.